Pryor 60 mg is a brand of Apalutamide, an oral non-steroidal anti-androgen agent, primarily used in the management of prostate cancer. Apalutamide is a relatively newer generation androgen receptor inhibitor developed to overcome resistance seen with earlier anti-androgens. By targeting androgen receptor pathways, it plays a pivotal role in slowing the progression of prostate cancer.

Pryor is usually supplied as 60 mg tablets, taken once daily as prescribed, and is intended for long-term management. It represents an important advancement for patients with prostate cancer that is sensitive to hormone signaling but continues to progress despite other interventions.

Mechanism of Action

Apalutamide belongs to a class of drugs known as androgen receptor inhibitors.

• It selectively binds to androgen receptors on prostate cancer cells, preventing activation by androgens such as testosterone and dihydrotestosterone.

• This blockade inhibits the transcription of androgen-responsive genes, thereby reducing cell proliferation and inducing cancer cell death.

• Unlike older agents, Apalutamide not only prevents androgen binding but also impairs receptor nuclear translocation and DNA binding, offering a more comprehensive blockade of androgen receptor signaling.

By effectively shutting down these pathways, Pryor (Apalutamide) reduces the growth and spread of prostate cancer cells that rely on androgen signals.

Uses

Pryor (Apalutamide) 60 mg is approved and commonly used for:

1. Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC):

   • For men whose prostate cancer has not spread to other parts of the body but continues to grow despite low testosterone levels achieved by surgical or medical castration.

2. Metastatic Castration-Sensitive Prostate Cancer (mCSPC):

   • For men whose prostate cancer has spread to distant sites but still responds to testosterone-lowering therapy.

In both scenarios, Apalutamide is typically used in combination with a gonadotropin-releasing hormone (GnRH) analog or following surgical castration to ensure suppression of testosterone production.

Adverse Effects

While Pryor (Apalutamide) is generally well tolerated, it is associated with a range of potential side effects. Understanding these is important for patients and caregivers to monitor and manage them proactively.

Common side effects:

• Fatigue (very common, may affect daily activities)

• Hot flushes

• Weight loss

• Joint pain (arthralgia) or muscle pain (myalgia)

• Hypertension (raised blood pressure)

• Rash, which may sometimes be extensive

• Falls and fractures, possibly linked to muscle weakness or balance issues